Group 1 - The core viewpoint of the news is that Haili Biological experienced a decline in stock price and trading volume, with significant details on financing and stockholder changes [1][2] Group 2 - On January 15, Haili Biological's stock fell by 1.83%, with a trading volume of 83.6 million yuan [1] - The financing data shows that on the same day, Haili Biological had a financing purchase amount of 9.52 million yuan, with a net financing purchase of 2.78 million yuan [1] - As of January 15, the total balance of margin trading for Haili Biological was 212 million yuan, with the financing balance accounting for 5.06% of the circulating market value, indicating a low level compared to the past year [1] - In terms of securities lending, Haili Biological had a securities lending repayment of 1,300 shares and a securities lending sell of 2,000 shares, with a total lending balance of 44.05 million yuan, also at a low level compared to the past year [1] Group 3 - As of September 30, the number of shareholders for Haili Biological increased to 33,800, a rise of 7.16%, while the average circulating shares per person decreased by 6.68% [2] - For the period from January to September 2025, Haili Biological reported a revenue of 150 million yuan, a year-on-year decrease of 14.15%, while the net profit attributable to the parent company was 20.33 million yuan, reflecting a slight increase of 0.77% [2] - Haili Biological has distributed a total of 209 million yuan in dividends since its A-share listing, with 107 million yuan distributed over the past three years [2] - Among the top ten circulating shareholders as of September 30, 2025, Guotai Zhongzheng Livestock Breeding ETF ranked as the fifth largest shareholder, increasing its holdings by 3.70 million shares to 10.23 million shares [2]

Group 1 - On November 20, Haili Biological experienced a trading volume of 34.61 million yuan, with a financing buy amount of 4.85 million yuan and a net financing buy of 756,600 yuan [1] - As of November 20, the total balance of margin trading for Haili Biological was 208 million yuan, with a financing balance of 207 million yuan, accounting for 4.64% of the circulating market value, indicating a low level compared to the past year [1] - Haili Biological's main business involves the research, production, and sales of animal vaccines, with revenue composition being 71.34% from oral vaccines and 28.61% from IVD [1] Group 2 - As of September 30, Haili Biological had 33,800 shareholders, an increase of 7.16% from the previous period, while the average circulating shares per person decreased by 6.68% to 19,196 shares [2] - For the period from January to September 2025, Haili Biological reported an operating income of 150 million yuan, a year-on-year decrease of 14.15%, while the net profit attributable to the parent company was 20.33 million yuan, reflecting a year-on-year increase of 0.77% [2] - Haili Biological has distributed a total of 209 million yuan in dividends since its A-share listing, with 107 million yuan distributed over the past three years [2]

Group 1 - The core viewpoint of the news highlights the recent trading performance and financial metrics of Haili Biological, indicating a slight increase in stock price and a net financing outflow on October 22 [1] - On October 22, Haili Biological's stock price rose by 0.28%, with a trading volume of 31.17 million yuan. The financing buy-in amount was 4.60 million yuan, while the financing repayment was 5.52 million yuan, resulting in a net financing outflow of 0.92 million yuan [1] - As of October 22, the total margin balance for Haili Biological was 219 million yuan, with the financing balance accounting for 4.79% of the circulating market value, which is below the 30th percentile level over the past year, indicating a low level of financing [1] Group 2 - As of June 30, Haili Biological had 31,500 shareholders, an increase of 0.14% from the previous period, while the average circulating shares per person decreased by 0.14% to 20,569 shares [2] - For the first half of 2025, Haili Biological reported an operating income of 110 million yuan, representing a year-on-year growth of 2.02%, and a net profit attributable to shareholders of 18.23 million yuan, which is a 20.56% increase year-on-year [2] - Haili Biological has distributed a total of 209 million yuan in dividends since its A-share listing, with 107 million yuan distributed over the past three years [3]